These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 36780114)

  • 21. Mid- and long-term (at least 12 months) follow-up of patients with spinal muscular atrophy (SMA) treated with nusinersen, onasemnogene abeparvovec, risdiplam or combination therapies: A systematic review of real-world study data.
    Erdos J; Wild C
    Eur J Paediatr Neurol; 2022 Jul; 39():1-10. PubMed ID: 35533607
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A phase 1 healthy male volunteer single escalating dose study of the pharmacokinetics and pharmacodynamics of risdiplam (RG7916, RO7034067), a SMN2 splicing modifier.
    Sturm S; Günther A; Jaber B; Jordan P; Al Kotbi N; Parkar N; Cleary Y; Frances N; Bergauer T; Heinig K; Kletzl H; Marquet A; Ratni H; Poirier A; Müller L; Czech C; Khwaja O
    Br J Clin Pharmacol; 2019 Jan; 85(1):181-193. PubMed ID: 30302786
    [TBL] [Abstract][Full Text] [Related]  

  • 23. An updated systematic review on spinal muscular atrophy patients treated with nusinersen, onasemnogene abeparvovec (at least 24 months), risdiplam (at least 12 months) or combination therapies.
    Giess D; Erdos J; Wild C
    Eur J Paediatr Neurol; 2024 Jul; 51():84-92. PubMed ID: 38905882
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy type 1 (STR1VE-EU): an open-label, single-arm, multicentre, phase 3 trial.
    Mercuri E; Muntoni F; Baranello G; Masson R; Boespflug-Tanguy O; Bruno C; Corti S; Daron A; Deconinck N; Servais L; Straub V; Ouyang H; Chand D; Tauscher-Wisniewski S; Mendonca N; Lavrov A;
    Lancet Neurol; 2021 Oct; 20(10):832-841. PubMed ID: 34536405
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Risdiplam for the Use of Spinal Muscular Atrophy.
    Kakazu J; Walker NL; Babin KC; Trettin KA; Lee C; Sutker PB; Kaye AM; Kaye AD
    Orthop Rev (Pavia); 2021; 13(2):25579. PubMed ID: 34745484
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Two-year efficacy and safety of risdiplam in patients with type 2 or non-ambulant type 3 spinal muscular atrophy (SMA).
    Oskoui M; Day JW; Deconinck N; Mazzone ES; Nascimento A; Saito K; Vuillerot C; Baranello G; Goemans N; Kirschner J; Kostera-Pruszczyk A; Servais L; Papp G; Gorni K; Kletzl H; Martin C; McIver T; Scalco RS; Staunton H; Yeung WY; Fontoura P; Mercuri E;
    J Neurol; 2023 May; 270(5):2531-2546. PubMed ID: 36735057
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Intrathecal Onasemnogene Abeparvovec for Sitting, Nonambulatory Patients with Spinal Muscular Atrophy: Phase I Ascending-Dose Study (STRONG).
    Finkel RS; Darras BT; Mendell JR; Day JW; Kuntz NL; Connolly AM; Zaidman CM; Crawford TO; Butterfield RJ; Shieh PB; Tennekoon G; Brandsema JF; Iannaccone ST; Shoffner J; Kavanagh S; Macek TA; Tauscher-Wisniewski S
    J Neuromuscul Dis; 2023; 10(3):389-404. PubMed ID: 36911944
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Polysomnography findings in children with spinal muscular atrophy after onasemnogene-abeparvovec.
    Leon-Astudillo C; Wagner M; Salabarria SM; Lammers J; Berthy J; Zingariello CD; Byrne BJ; Smith BK
    Sleep Med; 2023 Jan; 101():234-237. PubMed ID: 36442421
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The Japan Registry for Adult Subjects of Spinal Muscular Atrophy (jREACT-SMA): Protocol for a Longitudinal Observational Study.
    Sahashi K; Hashizume A; Kuwatsuka Y; Chinen M; Saotome-Nakamura A; Ando M; Katsuno M
    JMIR Res Protoc; 2022 Dec; 11(12):e38878. PubMed ID: 36520510
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Switching from Nusinersen to Risdiplam: A Croatian Real-World Experience on Effectiveness and Safety.
    Belančić A; Strbad T; Kučan Štiglić M; Vitezić D
    J Pers Med; 2024 Feb; 14(3):. PubMed ID: 38540986
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Longitudinal prospective cohort study to assess peripheral motor function with extensive electrophysiological techniques in patients with Spinal Muscular Atrophy (SMA): the SMA Motor Map protocol.
    Ros LAA; Goedee HS; Franssen H; Asselman FL; Bartels B; Cuppen I; van Eijk RPA; Sleutjes BTHM; van der Pol WL; Wadman RI
    BMC Neurol; 2023 Apr; 23(1):164. PubMed ID: 37095427
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Nusinersen: A Review in 5q Spinal Muscular Atrophy.
    Hoy SM
    CNS Drugs; 2021 Dec; 35(12):1317-1328. PubMed ID: 34850360
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cost-Effectiveness of Technologies for the Treatment of Spinal Muscular Atrophy: A Systematic Review of Economic Studies.
    Motta-Santos A; Noronha K; Reis C; Freitas D; Carvalho L; Andrade M
    Value Health Reg Issues; 2024 Jul; 42():100985. PubMed ID: 38669792
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Gene replacement therapy with onasemnogene abeparvovec in children with spinal muscular atrophy aged 24 months or younger and bodyweight up to 15 kg: an observational cohort study.
    Weiß C; Ziegler A; Becker LL; Johannsen J; Brennenstuhl H; Schreiber G; Flotats-Bastardas M; Stoltenburg C; Hartmann H; Illsinger S; Denecke J; Pechmann A; Müller-Felber W; Vill K; Blaschek A; Smitka M; van der Stam L; Weiss K; Winter B; Goldhahn K; Plecko B; Horber V; Bernert G; Husain RA; Rauscher C; Trollmann R; Garbade SF; Hahn A; von der Hagen M; Kaindl AM
    Lancet Child Adolesc Health; 2022 Jan; 6(1):17-27. PubMed ID: 34756190
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Safety and Efficacy of Nusinersen and Risdiplam for Spinal Muscular Atrophy: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
    Qiao Y; Chi Y; Gu J; Ma Y
    Brain Sci; 2023 Oct; 13(10):. PubMed ID: 37891788
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Adherence and Persistence Among Risdiplam-Treated Individuals with Spinal Muscular Atrophy: A Retrospective Claims Analysis.
    Pineda ED; To TM; Dickendesher TL; Shapouri S; Iannaccone ST
    Adv Ther; 2024 Jun; 41(6):2446-2459. PubMed ID: 38709394
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Selecting disease-modifying medications in 5q spinal muscular atrophy.
    Cartwright MS; Upadhya S
    Muscle Nerve; 2021 Oct; 64(4):404-412. PubMed ID: 34231920
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Drug treatment for spinal muscular atrophy types II and III.
    Wadman RI; van der Pol WL; Bosboom WM; Asselman FL; van den Berg LH; Iannaccone ST; Vrancken AF
    Cochrane Database Syst Rev; 2020 Jan; 1(1):CD006282. PubMed ID: 32006461
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Treatment of Spinal Muscular Atrophy].
    Ishiyama A
    Brain Nerve; 2023 May; 75(5):507-510. PubMed ID: 37194521
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Outcomes of early-treated infants with spinal muscular atrophy: A multicenter, retrospective cohort study.
    Goedeker NL; Rogers A; Fisher M; Arya K; Brandsema JF; Farah H; Farrar MA; Felker MV; Gibbons M; Hamid OA; Harmelink M; Herbert K; Kichula E; King K; Lakhotia A; Lee BH; Kuntz NL; Parsons J; Rehborg R; Veerapaniyan A; Zaidman CM
    Muscle Nerve; 2024 Dec; 70(6):1247-1256. PubMed ID: 39370660
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.